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Abstract
Background. Many studies throughout the world show that hyper-
tension is not effectively treated and controlled, which continued to
pose an important challenge in health systems in the world.
Design and methods. Population surveys were carried out in 2002
and 2012 in the Federation of Bosnia and Herzegovina (FBIH) on rep-
resentative sample at the age of 25-64. The surveys used systematic
stratified sample. Questionnaires and anthropometric measure proto-
cols were adapted from internationally recommended surveys.
Results. In the past ten years there has been a slight increase in
hypertension prevalence in researched population (41% vs. 42%).
Percentage of hypertensive male and female respondents who are not
aware of their hypertension actually dropped in the past decade from
54.3% to 51.4%. In 2002 total number of hypertensive respondents
aware of their hypertension included 8.1% of male respondents and
10.3% female respondents whose condition was not treated and this
rate effectively dropped during the 10-year period. Number of hyper-
tensive, treated, and uncontrolled respondents dropped as reported in
the 2012 survey; consequently percentage of hypertensive, treated,
and controlled respondents in the 2012 survey increased, in particular
in female population.
Conclusions. Investments in primary health care, improved avail-
ability, and improved quality of health care in the FBIH in the past 10
years can explain increased rate of hypertension detection and treat-
ment; however, efforts should be continued to introduce hypertension
screening programs and hypertension control programs.
Introduction 
High blood pressure (BP) accounts for almost 8 million deaths
annually worldwide, which makes up approximately 13% of total mor-
tality in the world. According to estimates from 2000, approximately 1
billion people suffered from hypertension and it is estimated that this
number could rise to 1.56 billion people by 2025.1-3 Untreated and
uncontrolled hypertension as a highly prevalent risk factor in cardio-
vascular diseases (CVD) causes cerebrovascular stroke, myocardial
infarction, and cardiac arrest, but also dementia, renal failure and
blindness.4
As the world is undergoing a substantial demographic transition
characterized by increased number of aging population, as a conse-
quence number of people suffering from hypertension increased from
600 million in 1980 to close to 1 billion in 2008. Increased hyperten-
sion prevalence is also caused by increased prevalence of unhealthy
living styles and behaviour in population, primarily unhealthy diet
habits, overweight and obesity, lack of physical activity, smoking, and
exposure to constant stress. All this eventually leads to increased num-
ber of CVD cases, which if not treated properly, may cause premature
death and disability, in particular in working population.5
However, many studies throughout the world show that hyperten-
sion is not effectively treated and controlled, which continued to pose
an important challenge in health systems in the world. National health
systems worldwide continue to struggle with inadequate hypertension
management.6-9
Routine health statistics in the Federation of Bosnia and
Herzegovina (FBIH) show that registered hypertension rate has been
steadily on the rise and so has been worrying upward trend of CVDs
plaguing the FBIH with high mortality rate among working active pop-
ulation.10 Available health statistical data on morbidity rates originate
from the primary health care and as such they are simply tip of an ice-
berg based on the patient-demand on health care, not on real health
needs of population. Health needs assessment of the population
requires additional sensitive research, such as cross-sectional popula-
tion surveys.
With the purpose of gathering consistent data on health status and
health needs of the FBIH population, two major population surveys
were carried out in the past decade on representative sample of adult
population. Surveys included monitoring of risk factors in develop-
ment of non-communicable diseases (NDC), including hypertension.
In addition to monitoring blood pressure and hypertension prevalence,
objective of the survey was also to evaluate extent of hypertension
detection, treatment, and control in the FBIH, as well as to highlight
changes in the 10-year trend.11
Design and methods
Two cross-sectional population surveys as household surveys were
conducted in 2002 and 2012 in the FBIH. In 2002 the target population
was adult population aged 25-64 years, while in the 2012 the target
population was adult population aged 18 years and over. 
Sample designing, conducted by the Federal Institute of Statistics
(FIS), was based on the estimated number of people, considering that
Significance for public health
In spite of wide knowledge of pathophysiology and epidemiology in develop-
ment of hypertension, ability to easily diagnose it, availability of efficient
medications, hypertension continues to have high prevalence and setting up
hypertension controls poses significant public health challenge. Recently
conducted cross-sectional population surveys in the Federation of Bosnia
and Herzegovina give us opportunity to follow the trend for hypertension and
implement public health measures to reduce or eliminate causes of high
blood pressure in population and at the same time with implementation of
medical treatment. 
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the last official census in Bosnia and Herzegovina (BIH) was in the
year 1991. In a survey from 2002, a three-stage stratified systematic
sample was applied, where the primary sampling units (first stage
units) were enumeration areas prepared by FIS. A random selection of
151 segments was drawn. At the second stage, from each segment 20
households were randomly selected using a random number method. At
the third stage, the survey team visited the selected households and
listed all the persons aged 25-64 years living in the household. The sur-
vey subject was then randomly selected amongst these eligible persons
living in the household. The total number of respondents was 2750
(1121 males and 1629 females), yielding response rate of 91%. 
In a survey from 2012 was applied the two-stage stratified systematic
sample, where the primary sampling units (first stage units) were enu-
meration areas prepared by FIS while secondary sampling units (sec-
ond stage units) were households. Secondary sampling units were
selected by systematic method, which meant that choice probabilities
were same. The survey covered a total of 3843 respondents aged 18 and
older, with an overall response rate of 97%. For purposes of comparison
for the results of these two surveys, it was performed the data analysis
for respondents aged 25-64, in total 2735 respondents, yielding
response rate of 80%. 
In addition to the questionnaires used to collect the data during face-
to-face interviews, respondents’ anthropometric values measures were
measured including BP. 
Questionnaires and anthropometric measure protocols were adapted
from internationally recommended surveys.12-16
Fieldwork for both surveys was conducted as households surveys in
the autumn-winter period.
BP was measured on a single occasion by trained interviewers using
a mercury sphygmomanometer with an appropriate cuff size (Riester
desk model), According to the WHO’s MONICA Protocol, BP was meas-
ured in sitting position, on the right hand and after 5 minute rest and
the values were read and recorded with the 2 mmHg accuracy. Two
blood pressure measurements were done in 2002 and three were done
in 2012 in intervals of 5 minutes. For analysis, it was used the mean of
the 2 measurements in 2002 or the mean of the last 2 when 3 measure-
ments were done.
The respondents were classified as hypertensive if their systolic
blood pressure (SBP) was higher than 140 mmHg and/or diastolic blood
pressure (DBP) was higher than 90 mm Hg and/or they were taking
antihypertensive therapy. Based on the defined hypertension criteria,
use of antihypertensive drugs, and value of  measured blood pressure,
the hypertensive respondents were divided into 4 groups: i) hyperten-
sive respondents, not aware of hypertension; ii) hypertensive respon-
dents, aware of hypertension, untreated; iii) hypertensive respondents,
treated, uncontrolled; and iv) hypertensive respondents, treated, con-
trolled. 
In addition to these definitions, other definitions were used of
European Society of Hypertension (ESH) and the European Society of
Cardiology (ESC) from 2013, whereby hypertension was classified in 3
grades. According to these definitions, grade I hypertension is a condi-
tion in which respondents reported values of SBP of 140-159 mmHg
and/or DBP of 90-99 mmHg; grade II hypertension is a condition in
which respondents reported values of SBP of 160-179 mmHg and/or
DBP of 100-109 mmHg; and grade III hypertension is a condition in
which respondents reported values of SKP >180 mmHg and/or DBP
>110 mmHg.17Statistical analysis
The obtained data were statistically analysed using SPSS 20 for
Windows. Primary survey variables were respondents stratified on the
basis of sex and age (four 10-year age groups - 25-34, 35-44, 45-54, and
55-64). Frequencies of awareness, treatment, or control were assessed
on the basis of 10-year age groups. Results are reported as proportion
and confidence interval (CI). Differences in frequency and sample
means were tested by the chi-square test and ANOVA (P<0.05 was con-
sidered to be statistically significant). 
Results Hypertension prevalence
In the 2002 survey hypertension prevalence in adult population
reached 41%, similar as in the 2012 survey (42%). The prevalence of
hypertension among male respondents in 2002 was 35.7% and among
female respondents was 45.3%. In 2012, the prevalence of hypertension
among male respondents was 43.9% and was higher than in 2002,
while in 2012 the prevalence of hypertension among female respon-
dents was 37.5% and was lower than in 2002. These differences were
statistically significant (P<0.01) (Figure 1) 
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Figure 1. Hypertension prevalence by sex and age. Male χ2(3)=113.3, P<0.0001, Female χ2(3)=377.6, P<0.0001.
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Hypertension awareness, treatment and control
Percentage of hypertensive male respondents who are not aware of
their hypertension in the past ten years dropped from 63.4% to 59.7%,
and in female respondents from 49.4% to 42.8%. The prevalence of
hypertension awareness significantly increased with age in both male
and female respondents.
In the 2002 survey in all hypertensive respondents who were aware
of their hypertension, 8.1% of male respondents and 10.3% female
respondents were not treated. Percent of hypertensive respondents
who were treated was higher in female respondents (40.3%) than male
respondents (28.5%). There were more hypertensive, treated, uncon-
trolled respondents in older age groups (age 45-64) and the percentage
significantly increased with age of respondents. Percent of hyperten-
sive treated and controlled respondents was low (males 4.8% vs.
females 6.1%) and there was no significant difference by age or sex.
In the 2012 survey, in all hypertensive respondents who were aware
of their hypertension, 4.7% of male respondents and 3% of female
respondents was not treated, which is lower compared to the 2002 sur-
vey, in particular in females and there was significant difference by age
or sex. Percent of hypertensive respondents who were treated was
higher in female respondents (54.2%) than in male respondents
(35.5%). Percentage of hypertensive, treated, uncontrolled respondents
was higher in older age groups (age 45-64) and the percentage signif-
icantly increased with age of respondents. Percent of hypertensive
treated and controlled respondents in males were 9%, and in females
was 22.2%, which is substantially higher than that of reported in the
2002 survey (Table 1).
According to the definitions of European Society of Hypertension
(ESH) and the European Society of Cardiology (ESC) from 2013, hyper-
tension is classified in three grades: In the 2002 survey, prevalence of
Grade 1 hypertension was equal in both female and male respondents. 
Proportion of respondents with grade I hypertension statistically
increased significantly with age in both female and male respondents
(P<0.0001). Ten years later, prevalence of grade I hypertension
increased in male respondents (22.6% vs. 30.1%), while in female
respondents prevalence of hypertension decreased (22.4% vs. 20.9%).
Prevalence of grade II and grade III hypertension reported in the 2002
survey was higher in females and these values decreased in the 2012
survey and in male respondents grade II and grade III hypertension
prevalence showed stagnation (Table 2). 
Discussion and Conclusions
The aim of the paper was to estimate prevalence, awareness, treat-
ment and control of hypertension in the FBIH over the past decade. 
Two population surveys based on internationally methodology were
carried out in 2002 and 2012. on a representative sample of adult pop-
ulation in the FBIH. Limitation of the survey is reflected in the catego-
rization of hypertensive respondents based on one off blood pressure
measurement, which in fact may lead to overrated hypertension levels,
especially in patients who reported threshold values of SBP of 140
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Table 1. Awareness, treatment and control of hypertension by sex and age.
Sex, age                Hypertensive,                             Hypertensive,  Hypertensive,                      Hypertensive, 
                                 not aware                                 not treated    treated, not controlled treated, controlled
                         n.            %       (95% CI)              n.           %    (95% CI)           n.         %       (95% CI)             n.        %         (95% CI)
2002
Male                                                                                                                                                                                                                                                                    
     25-34                  19             95.0      (83.3-100.0)                  0              0.0                                        1           5.0          (0.0-16.7)                   0           0.0                     
     35-44                  75             87.2       (79.8-93.8)                   6              7.0      (2.3-12.9)                1           1.2           (0.0-3.9)                    4           4.7             (1.1-9.6)
     45-54                  81             62.8       (54.2-71.2)                  15            11.6     (6.3-17.6)               28         21.7        (14.8-29.0)                  5           3.9             (0.8-7.5)
     55-64                  74             46.8       (39.0-54.7)                  11             7.0      (3.2-11.2)               63         39.9        (32.3-47.6)                 10          6.3            (2.8-10.3)
     Total                  249            63.4       (58.6-68.1)                  32             8.1      (5.5-10.9)               93         23.7        (19.5-28.0)                 19          4.8             (2.8-7.1)
Female                                                                                                                                                                                                                                                               
     25-34                  29             76.3       (61.5-89.2)                   6             15.8     (5.3-28.6)                0           0.0                                              3           7.9            (0.0-17.6)
     35-44                  80             63.0       (54.4-71.2)                  16            12.6     (7.1-18.8)               23         18.1        (11.7-25.0)                  8           6.3            (2.4-10.9)
     45-54                 126            53.4       (47.1-59.8)                  27            11.4     (7.6-15.7)               72         30.5        (24.8-36.5)                 11          4.7             (2.1-7.6)
     55-64                 123             38.        (32.7-43.3)                  26             8.0      (5.2-11.1)              153        47.2        (41.8-52.7)                 22          6.8             (4.2-9.6)
     Total                  358            49.4       (45.6-53.0)                  75            10.3     (8.2-12.6)              248        34.2        (30.7-37.7)                 44          6.1             (4.4-7.8)
Total 2002              607            54.3       (51.3-57.2)                 107            9.6      (7.9-11.3)              341        30.5        (27.7-33.3)                 63          5.6             (4.3-7.0)
2012
Male                                                                                                                                                                                                                                                                    
     25-34                  43             84.3       (73.4-93.8)                   5              9.8      (2.2-18.9)                3           5.9          (0.0-13.2)                   0           0.0                     
     35-44                  74             70.5       (61.5-78.9)                   8              7.6      (2.9-13.0)               13         12.4         (6.3-18.8)                  10          9.5            (4.2-15.6)
     45-54                 107            64.1       (56.6-71.3)                   5              3.0       (0.6-5.8)                44         26.3        (19.9-33.3)                 11          6.6            (3.0-10.6)
     55-64                 107            46.3       (39.8-52.8)                   8              3.5       (1.3-6.0)                87         37.7        (31.1-44.0)                 29         12.6           (8.5-17.0)
     Total                  331            59.7       (55.7-63.8)                  26             4.7       (3.0-6.5)               147        26.5        (22.9-30.3)                 50          9.0            (6.7-11.5)
Female                                                                                                                                                                                                                                                               
     25-34                  25             71.4       (55.2-86.1)                   4             11.4     (2.5-23.1)                3           8.6          (0.0-19.0)                   3           8.6            (0.0-18.9)
     35-44                  43             66.2       (54.1-77.8)                   3              4.6      (0.0-10.4)                8          12.3         (4.8-20.8)                  11          16.            (8.2-26.8)
     45-54                  83             43.9       (36.8-51.0)                   4              2.1       (0.5-4.4)                57         30.2        (23.7-36.8)                 45         23.8          (17.9-30.9)
     55-64                  78             31.7       (25.9-37.5)                   5              2.0       (0.4-4.0)               103        41.9        (35.7-48.1)                 60         24.4          (19.1-30.0)
     Total                  229            42.8       (38.7-46.9)                  16             3.0       (1.6-4.6)               171        32.0        (28.1-35.9)                119        22.2          (18.7-25.9)
Total 2012              560            51.4       (48.4-54.4)                  42             3.9       (2.8-5.0)               318        29.2        (26.6-31.9)                169        15.5          (13.4-17.7)
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mmHg and/or DBP of 90 mmHg. Although cross-sectional surveys are
not ideal tools for evaluation, they are necessary to obtain information
about individuals who have no contact with health professionals in
health care institution, individuals who are not aware of their hyper-
tension, level of treatment and control of hypertension. 
Surveys showed that hypertension prevalence in the FBIH is quite
high; in the 2012 survey it was reported at 42% which is consistent with
median values of hypertension in Europe and within reference value of
SBP ≥140 mmHg and/or DBP ≥90 mmHg. Average hypertension preva-
lence in Europe in the past ten years was 44% and it ranged from 55%
in Germany to 38% in Italy. In the US and Canada hypertension preva-
lence values are considerably lower at 29% and 19% respectively.18-20
Compared to transition countries of the Southeast Europe, hyperten-
sion prevalence in the FBIH is high, in particular when compared to
Slovenia, Croatia, and Albania, but it is still lower than in Serbia.21-24 In
the neighbouring countries where lower hypertension prevalence is
reported which is still not statistically significant but is very important
in terms of epidemiology.
Of all hypertensive respondents included in the 2012 survey half of
them still was not aware that they actually had hypertension, which is
slight improvement compared to results of the 2002 survey (51.4% vs.
54.3%). These values are still considerably higher than in the US and
Canada.25 Among respondents who were aware of their hypertension, a
total of four-fifths of them were treated and nearly one-fifth of them
were controlled. Although there has been significant progress in
increasing awareness, detection, treatment, and control of hyperten-
sion, these results showed that still do not have adequate blood pres-
sure control. Percentage of hypertensive respondents who were aware
of their hypertension and not treated was significantly lower in 2012
survey which is explained by increased availability of antihypertensive
drugs in the last ten years in the FBIH. Similarly, hypertensive respon-
dents who were treated were substantially higher and the results effec-
tively improved when compared to the 2002 survey. The most signifi-
cant improvement was in increasing percentage of treated and con-
trolled female respondents over the ten years (6.1% vs. 22.2%).
Generally, females are more aware of their hypertension, they are treat-
ed more often and their hypertension is better controlled that in males
which corresponds with the results of population studies in many coun-
tries.26,27
According to the hypertension classification of the European Society
of Hypertension (ESH) and the European Society of Cardiology (ESC)
from 2013, the results showed that the values of severe forms of hyper-
tension reported in the 2012 survey were more common in males than
in females and that the results significantly changed compared to val-
ues reported in the 2002 survey with noticeable increase of prevalence,
in particular of grade 1 hypertension in males. 
A significant progress has been made through primary health care
using clinical guidelines applying better individual approach, but it still
needs to work on population approach in developing a formal pro-
gramme to control hypertension.
Investment of continued efforts to ensure further strengthening of
integrated hypertension management, including also individual and
population approaches, is necessity. 
Changes to lifestyle can by all means lower BP and prevent hyperten-
sion while adequate pharmacological treatment can reduce cardiovas-
cular episodes cause by hypertension. Investments in primary heath
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Table 2. Hypertension prevalence, by age and sex (ESH and ESC classification).
Age                                     Grade I                                                                  Grade II                                                       Grade III
                            n.                %           (95% CI)                             n.                  %         (95% CI)                       n.               %          (95% CI)
2002
Male                                                                                                                                                                                                                                                                                 
         25-34                   17                   10.3             (5.9-15.1)                                        2                        1.2             (0.0.-3.1)                                 1                    0.6               (0.0-2.0)
         35-44                   65                   19.1            (15.0-23.4)                                      14                       4.1             (2.2-6.4)                                 3                    0.9               (0.0-2.0)
         5-54                     89                   27.9            (23.0-32.9)                                      28                       8.8            (5.8-12.0)                                7                    2.2               (0.7-4.0)
         55-64                   78                   28.1            (22.7-33.3)                                      47                      16.9          (12.7-21.5)                              23                   8.3              (5.1-11.6)
         Total                   249                  22.6            (20.2-25.1)                                      91                       8.3             (6.7-9.9)                                34                   3.1               (2.1-4.1)
Female                                                                                                                                                                                                                                                                            
         25-34                   31                    9.8              (6.7-13.2)                                        4                        1.3             (0.3-2.7)                                 0                    0.0                       
         35-44                   87                   19.6            (15.9-23.3)                                      21                       4.7             (2.8-6.8)                                11                   2.5               (1.1-4.0)
         45-54                  119                  28.5            (24.2-32.9)                                      62                      14.8          (11.5-18.3)                              44                  10.5             (7.7-13.6)
         55-64                  122                  28.8            (24.4-33.2)                                     110                    25.9          (21.7-30.3)                              70                  16.5            (13.1-20.1)
         Total                   359                  22.4            (20.4-24.5)                                     197                    12.3          (10.7-13.9)                             125                  7.8               (6.5-9.1)
Total 2002                   608                  22.5            (20.9-24.1)                                     288                    10.7           (9.5-11.8)                              159                  5.9               (5.0-6.8)
2012
Male                                                                                                                                                                                                                                                                                 
         25-34                   38                   12.5             (8.9-16.3)                                        9                        3.0             (1.3-5.0)                                 3                    1.0               (0.0-2.3)
         35-44                   83                   27.0            (22.1-32.0)                                      12                       3.9             (1.9-6.2)                                 5                    1.6               (0.3-3.2)
         45-54                  122                  35.7            (30.7-40.9)                                      26                       7.6            (4.9-10.6)                               11                   3.2               (1.5-5.2)
         55-64                  137                  44.2            (38.7-49.8)                                      59                      19.0          (14.7-23.4)                              17                   5.5               (3.1-8.1)
         Total                   380                  30.1            (27.6-32.6)                                     106                      8.4             (6.9-9.9)                                36                   2.9               (2.0-3.8)
Female                                                                                                                                                                                                                                                                            
         25-34                   27                    8.4              (5.5-11.5)                                        5                        1.5             (0.3-3.0)                                 1                    0.3               (0.0-1.0)
         35-44                   42                   12.6             (9.1-16.4)                                       12                       3.6             (1.8-5.7)                                 1                    0.3               (0.0-1.0)
         45-54                  104                  24.9            (20.9-29.1)                                      40                       9.6            (6.8-12.5)                               10                   2.4               (1.0-4.0)
         55-64                  125                  35.5            (30.6-40.5)                                      49                      13.9          (10.4-17.6)                              21                   6.0               (3.6-8.5)
         Total                   298                  20.9            (18.8-23.0)                                     106                      7.4             (6.1-8.8)                                33                   2.3               (1.6-3.1)
Total 2012                   678                  25.2            (23.6-26.8)                                     212                      7.9             (6.9-8.9)                                69                   2.6               (2.0-3.2)
No
 c
m
erc
ial
 us
e o
nly
[page 150]                                               [Journal of Public Health Research 2014; 3:323]                             
care, increased availability and improved quality of health care in the
FBIH in the past ten years can explain increased hypertension detec-
tion and treatment rates; however, efforts should be continued to intro-
duce hypertension screening programs and hypertension control pro-
grams. Additional attention should be paid to detection of hypertension
at early age, in particular in male population.28,29
At the same time public health measures should be implemented to
reduce or eliminate causes of high pb, including reduced salt intake,
increased fruit and vegetable intake, promotion of physical activity, all
of which are recommendations of recently adopted WHO’s Action plan
for implementation of the European Strategy for the Prevention and
Control of Non-communicable Diseases 2012-2016.30 Introduction of
cost-effective prevention programs for hypertension management in
daily operations of primary health care teams will untimely improve
quality of health care and ensure long-term reduction of cardiovascular
and cerebrovascular disease burden.
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